JP2020507596A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020507596A5 JP2020507596A5 JP2019543851A JP2019543851A JP2020507596A5 JP 2020507596 A5 JP2020507596 A5 JP 2020507596A5 JP 2019543851 A JP2019543851 A JP 2019543851A JP 2019543851 A JP2019543851 A JP 2019543851A JP 2020507596 A5 JP2020507596 A5 JP 2020507596A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding fragment
- subject
- pharmaceutical composition
- bladder cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 83
- 239000000427 antigen Substances 0.000 claims description 52
- 102000036639 antigens Human genes 0.000 claims description 52
- 108091007433 antigens Proteins 0.000 claims description 52
- 239000012634 fragment Substances 0.000 claims description 52
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 42
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 40
- 206010005003 Bladder cancer Diseases 0.000 claims description 39
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 37
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 21
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 20
- 229950009791 durvalumab Drugs 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 10
- 229910052697 platinum Inorganic materials 0.000 claims description 10
- 229950007217 tremelimumab Drugs 0.000 claims description 10
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 9
- 238000011275 oncology therapy Methods 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 6
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 6
- 229960004316 cisplatin Drugs 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 230000001394 metastastic effect Effects 0.000 claims description 5
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 5
- 210000000626 ureter Anatomy 0.000 claims description 5
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 4
- 229960005277 gemcitabine Drugs 0.000 claims description 4
- 210000000244 kidney pelvis Anatomy 0.000 claims description 3
- 210000003708 urethra Anatomy 0.000 claims description 3
- 210000003932 urinary bladder Anatomy 0.000 claims description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 2
- 229940009456 adriamycin Drugs 0.000 claims description 2
- 229960004562 carboplatin Drugs 0.000 claims description 2
- 190000008236 carboplatin Chemical compound 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- 229960003048 vinblastine Drugs 0.000 claims description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 2
- 210000003803 urachus Anatomy 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 15
- 230000004044 response Effects 0.000 description 15
- 230000004083 survival effect Effects 0.000 description 11
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 230000004797 therapeutic response Effects 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023216425A JP2024038034A (ja) | 2017-02-16 | 2023-12-22 | 膀胱癌の抗ｐｄ－ｌ１抗体治療 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762459700P | 2017-02-16 | 2017-02-16 | |
| US62/459,700 | 2017-02-16 | ||
| PCT/US2018/018513 WO2018152415A1 (en) | 2017-02-16 | 2018-02-16 | Anti-pd-l1 antibody treatment of bladder cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023216425A Division JP2024038034A (ja) | 2017-02-16 | 2023-12-22 | 膀胱癌の抗ｐｄ－ｌ１抗体治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020507596A JP2020507596A (ja) | 2020-03-12 |
| JP2020507596A5 true JP2020507596A5 (enExample) | 2021-04-01 |
Family
ID=63169615
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019543851A Pending JP2020507596A (ja) | 2017-02-16 | 2018-02-16 | 膀胱癌の抗ｐｄ−ｌ１抗体治療 |
| JP2023216425A Pending JP2024038034A (ja) | 2017-02-16 | 2023-12-22 | 膀胱癌の抗ｐｄ－ｌ１抗体治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023216425A Pending JP2024038034A (ja) | 2017-02-16 | 2023-12-22 | 膀胱癌の抗ｐｄ－ｌ１抗体治療 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20190359715A1 (enExample) |
| EP (1) | EP3582805A4 (enExample) |
| JP (2) | JP2020507596A (enExample) |
| KR (3) | KR20190117014A (enExample) |
| CN (2) | CN118001389A (enExample) |
| AU (2) | AU2018221822A1 (enExample) |
| CA (1) | CA3052652A1 (enExample) |
| EA (1) | EA201991870A1 (enExample) |
| IL (3) | IL302777A (enExample) |
| MA (1) | MA47509A (enExample) |
| SG (1) | SG11201907211TA (enExample) |
| WO (1) | WO2018152415A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS59134B1 (sr) * | 2014-05-13 | 2019-09-30 | Medimmune Ltd | Anti-b7-h1 i anti-ctla-4 antitela za tretman nesitnoćelijskog kancera pluća |
| MA47509A (fr) * | 2017-02-16 | 2019-12-25 | Medimmune Llc | Traitement par anticorps anti-pd-l1 du cancer de la vessie |
| BR112019025188A2 (pt) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
| WO2021234150A1 (en) * | 2020-05-21 | 2021-11-25 | Astrazeneca Ab | Tumor mutational burden associated with sensitivity to immunotherapy in locally advanced or metastatic urothelial carcinoma |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7947261B2 (en) * | 2003-05-23 | 2011-05-24 | Nektar Therapeutics | Conjugates formed from polymer derivatives having particular atom arrangements |
| RS59134B1 (sr) * | 2014-05-13 | 2019-09-30 | Medimmune Ltd | Anti-b7-h1 i anti-ctla-4 antitela za tretman nesitnoćelijskog kancera pluća |
| SG10201810615VA (en) * | 2015-02-26 | 2019-01-30 | Merck Patent Gmbh | Pd-1 / pd-l1 inhibitors for the treatment of cancer |
| HK1248773A1 (zh) * | 2015-05-29 | 2018-10-19 | 豪夫迈‧罗氏有限公司 | 用於癌症的治疗和诊断方法 |
| EP3387155A4 (en) * | 2015-12-10 | 2019-06-12 | Definiens AG | METHOD FOR THE TREATMENT AND SELECTION OF PATIENTS THAT APPLY TO IMMUNE-ACTED CANCER THERAPY |
| AU2017257505B2 (en) * | 2016-04-25 | 2020-05-14 | Medimmune, Llc | Compositions comprising coformulation of anti-PD-L1 and Anti-CTLA-4 antibodies |
| MA47509A (fr) * | 2017-02-16 | 2019-12-25 | Medimmune Llc | Traitement par anticorps anti-pd-l1 du cancer de la vessie |
-
2018
- 2018-02-16 MA MA047509A patent/MA47509A/fr unknown
- 2018-02-16 KR KR1020197026803A patent/KR20190117014A/ko not_active Ceased
- 2018-02-16 CN CN202410133870.XA patent/CN118001389A/zh active Pending
- 2018-02-16 WO PCT/US2018/018513 patent/WO2018152415A1/en not_active Ceased
- 2018-02-16 AU AU2018221822A patent/AU2018221822A1/en not_active Abandoned
- 2018-02-16 IL IL302777A patent/IL302777A/en unknown
- 2018-02-16 SG SG11201907211TA patent/SG11201907211TA/en unknown
- 2018-02-16 IL IL320916A patent/IL320916A/en unknown
- 2018-02-16 US US16/486,222 patent/US20190359715A1/en not_active Abandoned
- 2018-02-16 JP JP2019543851A patent/JP2020507596A/ja active Pending
- 2018-02-16 CN CN201880011428.2A patent/CN110290803A/zh active Pending
- 2018-02-16 KR KR1020237034594A patent/KR20230145547A/ko not_active Ceased
- 2018-02-16 EP EP18753778.2A patent/EP3582805A4/en active Pending
- 2018-02-16 KR KR1020257004753A patent/KR20250025517A/ko active Pending
- 2018-02-16 EA EA201991870A patent/EA201991870A1/ru unknown
- 2018-02-16 CA CA3052652A patent/CA3052652A1/en active Pending
-
2019
- 2019-08-04 IL IL268460A patent/IL268460A/en unknown
-
2022
- 2022-04-14 US US17/720,903 patent/US20220332828A1/en active Pending
-
2023
- 2023-12-22 JP JP2023216425A patent/JP2024038034A/ja active Pending
-
2025
- 2025-02-21 AU AU2025201227A patent/AU2025201227A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Guan et al. | Adverse events of monoclonal antibodies used for cancer therapy | |
| Chen et al. | Adverse effects of anticancer agents that target the VEGF pathway | |
| JP2018522850A5 (enExample) | ||
| Wehler et al. | A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non‐small cell lung cancer | |
| Soularue et al. | Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study | |
| Souglakos et al. | Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy | |
| Song et al. | Current status and prospects of camrelizumab, a humanized antibody against programmed cell death receptor 1 | |
| JP2013520442A5 (enExample) | ||
| JP2020507596A5 (enExample) | ||
| CN108498532A (zh) | 骨髓抑制的治疗 | |
| Hyung et al. | Clinical benefit of maintenance therapy for advanced biliary tract cancer patients showing no progression after first-line gemcitabine plus cisplatin | |
| WO2014142220A1 (ja) | 抗腫瘍剤 | |
| JP2024038034A5 (enExample) | ||
| Lignon et al. | Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma | |
| CA2939464A1 (en) | Use of anti-ccr5 antibodies in graft versus host disease | |
| Rose et al. | A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study | |
| Smith et al. | Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody | |
| Fujimoto et al. | A phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma: a study protocol | |
| Sun et al. | Programmed cell death 1 (PD‐1)/PD‐ligand 1 (PD‐L1) inhibitors‐related pneumonitis in patients with advanced non–small cell lung cancer | |
| Nardi et al. | FOLFOX-4 regimen as first-line chemotherapy in elderly patients with advanced gastric cancer: a safety study | |
| Umemura et al. | Modified FOLFIRINOX for locally advanced and metastatic pancreatic cancer patients resistant to gemcitabine and S-1 in Japan: a single institutional experience | |
| Kojima et al. | Phase I dose‐escalation trial of Sym004, an anti‐EGFR antibody mixture, in Japanese patients with advanced solid tumors | |
| WO2023134706A1 (zh) | 抗trop-2抗体偶联药物和其他治疗剂的组合用途 | |
| Shukuya et al. | Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients | |
| JP2024174997A (ja) | Ｃｄ４７阻害物質、免疫チェックポイント阻害物質および標準療法の併用によるがん治療法 |